Patents by Inventor Olivier Civelli
Olivier Civelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9610281Abstract: A method of treating nervous system diseases associated with dopamine receptors comprising administering a patent in need a compound having a structure of general formula (I) or a pharmaceutical acceptable salt, hydrate, or solvate thereof in a pharmaceutically effective amount, and a method of making the compound having the structure of general formula (I) or a pharmaceutical acceptable salt, hydrate, or solvate thereof. The compound of formula (I) has multiple pharmacological functions such as the functions of activating opioid receptors and blocking dopamine D2 receptors, and has good physicochemical properties and oral bioavailability. General animal experiments show that such a compound has significant and long-lasting analgesic and calming effects and can be used to treat pain and other mental illnesses.Type: GrantFiled: November 19, 2012Date of Patent: April 4, 2017Assignees: DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES, UNIVERSITY OF CALIFORNIA, IRVINEInventors: Xinmiao Liang, Chaoran Wang, Xiuli Zhang, Yan Zhang, Zhiwei Wang, Olivier Civelli, Yanxiong Ke, Lien Wang
-
Publication number: 20150164870Abstract: A method of treating nervous system diseases associated with dopamine receptors comprising administering a patent in need a compound having a structure of general formula (I) or a pharmaceutical acceptable salt, hydrate, or solvate thereof in a pharmaceutically effective amount, and a method of making the compound having the structure of general formula (I) or a pharmaceutical acceptable salt, hydrate, or solvate thereof. The compound of formula (I) has multiple pharmacological functions such as the functions of activating opioid receptors and blocking dopamine D2 receptors, and has good physicochemical properties and oral bioavailability. General animal experiments show that such a compound has significant and long-lasting analgesic and calming effects and can be used to treat pain and other mental illnesses.Type: ApplicationFiled: November 19, 2012Publication date: June 18, 2015Inventors: Xinmiao Liang, Chaoran Wang, Xiuli Zhang, Yan Zhang, Zhiwei Wang, Olivier Civelli, Yanxiong Ke, Lien Wang
-
Patent number: 9012407Abstract: Compositions and methods that act on Neuropeptide S receptors (NPSR) (also known as “TGR23” or “vasopressin receptor-related receptor 1 (VRR1)”) to cause desired effects in the bodies of human or animal subjects. Neuropeptide S (NPS) and other agonists of the NPSR may be administered to cause arousal, awakening, alertness, spontaneous movement, bronchoconstriction, contraction of bronchial smooth muscle or other effects. Antagonists of the NPSR may be administered to cause decreased arousal, decreased awakening, decreased alertness, decreased spontaneous movement, sleep, somnolence, sedation, anxiolytic effects, normalized sleep patterns, normalized sleep stages, increased duration of sleep, bronchodilation, relaxation of broncheal smooth muscle or other effects.Type: GrantFiled: April 25, 2005Date of Patent: April 21, 2015Assignee: The Regents of the University of CaliforniaInventors: Olivier Civelli, Rainer K. Reinscheid, Yanling Xu
-
Publication number: 20100056455Abstract: Compositions and methods that act on Neuropeptide S reseptors (NPSR) (also known as or “TGR23” or “vasopressin receptor-related receptor 1 (VRR1)”) to cause desired effects in the bodies of human or animal subjects. Neuropeptide S (NPS) and other agonists of the NPSR may be administered to cause arousal, awakening, alertness, spontaneous movement, bronchoconstriction, contraction of bronchial smooth muscle or other effects. Antagonists of the NPSR may be administered to cause decreased arousal, decreased awakening, decreased alertness, decreased spontaneous movement, sleep, somnolence, sedation, anxiolytic effects, normalized sleep patterns, normalized sleep stages, increased duration of sleep, bronchodilation, relaxation of broncheal smooth muscle or other effects.Type: ApplicationFiled: April 25, 2005Publication date: March 4, 2010Inventors: Olivier Civelli, Rainer K Reinscheld, Yanling Xu
-
Patent number: 7053189Abstract: The present invention is directed toward antibodies, particularly monoclonal antibodies, which bind specifically to a novel human D4 dopamine receptor in sensitive and specific immunological assays useful for the detection, quantization, and characterization of human D4 dopamine and dopamine analogues.Type: GrantFiled: August 20, 2002Date of Patent: May 30, 2006Assignee: Oregon Health & Sciences UniversityInventors: Olivier Civelli, Hubert Henri-Marie Van Tol
-
Patent number: 6884596Abstract: The invention provides methods of screening for a compound for promoting wakefulness in a mammal. The method is practiced by providing a compound that is a PrRP receptor agonist and determining the ability of the compound to promote wakefulness. Also provided by the invention are methods of screening for a compound for promoting sleep in a mammal. The methods are practiced by providing a compound that is a PrRP receptor antagonist and determining the ability of the compound to promote sleep. In addition, the invention provides a method of promoting wakefulness in a mammal. The method is practiced by administering to a mammal an effective amount of a PrRP receptor agonist. The invention further provides a method of promoting sleep in a mammal. The method is practiced by administering to a mammal an effective amount of a PrRP receptor antagonist.Type: GrantFiled: August 17, 2001Date of Patent: April 26, 2005Assignee: The Regents of the University of CaliforniaInventors: Olivier Civelli, Steven Lin
-
Patent number: 6790608Abstract: The present invention provides an isolated nucleic acid molecule containing a nucleotide sequence which encodes an ADP-glucose receptor, and isolated polynucleotides therefrom. Also provided is an isolated ADP-glucose receptor polypeptide, an isolated immunogenic peptide therefrom, and antibodies specific therefor. The invention also provides a method of identifying an ADP-glucose receptor agonist or antagonist, by contacting an ADP-glucose receptor with one or more candidate compounds under conditions suitable for detection of a G-protein coupled signal in response to ADP-glucose, and identifying a candidate compound that alters production of the signal. Further provided is a method of identifying an ADP-glucose receptor ligand, by contacting an ADP-glucose receptor with one or more candidate compounds under conditions suitable for detecting selective binding of ADP-glucose to ADP-glucose receptor, and identifying a candidate compound that selectively binds the ADP-glucose receptor.Type: GrantFiled: February 9, 2001Date of Patent: September 14, 2004Assignee: The Regents of the University of CaliforniaInventors: Olivier Civelli, Hans-Peter Nothacker, Zhiwei Wang, Rainer Reinscheid
-
Publication number: 20030171270Abstract: The invention provides a substantially pure Prolactin Releasing Peptide (PrRP) functional analog which suppresses absence seizures in a mammal, and related pharmaceutical compositions. The invention also provides a method of controlling absence seizures in a mammal, by administering to a mammal susceptible to absence seizures an effective amount of PrRP or a PrRP functional analog. Also provided are methods of identifying a compound that modulates AMPA receptor signaling in a mammal, by providing a compound that is a PrRP or PrRP functional analog, and determining the ability of the compound to modulate AMPA receptor signaling. The invention also provides methods of identifying a compound for controlling absence seizures in a mammal, by providing a compound that is a PrRP or PrRP functional analog, and determining the ability of the compound to control absence seizures in a mammal. Also provided are pharmaceutical compositions for controlling absence seizures in a mamma.Type: ApplicationFiled: March 12, 2002Publication date: September 11, 2003Applicant: Regents of the University of CaliforniaInventors: Olivier Civelli, Steven Lin
-
Publication number: 20030059845Abstract: The present invention is directed toward the isolation, characterization and pharmacological use of the human D4 dopamine receptor. The nucleotide sequence of the gene corresponding to this receptor and alleleic variant thereof are provided by the invention. The invention also includes recombinant eukaryotic expression constructs capable of expressing the human D4 dopamine receptor in cultures of transformed eukaryotic cells. The invention provides cultures of transformed eukaryotic cells which synthesize the human D4 dopamine receptor, and methods for characterizing novel psychotropic compounds using such cultures.Type: ApplicationFiled: August 20, 2002Publication date: March 27, 2003Inventors: Olivier Civelli, Hubert Henri-Marie Van Tol
-
Publication number: 20030040022Abstract: A mammalian D2 dopamine receptor gene has been cloned. Thus, DNA sequences encoding all or a part of the dopamine receptor are provided, as well as the corresponding polypeptide sequences and methods for producing the same both synthetically and via expression of a corresponding sequence from a host transformed with a suitable vector carrying the corresponding DNA sequence. The various structural information provided by this invention enables the preparation of labeled or unlabeled immunospecific species, particularly antibodies, as well as nucleic acid probes labeled in conventional fashion. Pharmaceutical compositions and methods of using various products of this invention are also provided.Type: ApplicationFiled: January 29, 2002Publication date: February 27, 2003Applicant: Oregon Health and Sciences UniversityInventors: Olivier Civelli, James R. Bunzow, David K. Grandy, Curtis A. Machida
-
Publication number: 20020123096Abstract: A mammalian D2 dopamine receptor gene has been cloned. Thus, DNA sequences encoding all or a part of the dopamine receptor are provided, as well as the corresponding polypeptide sequences and methods for producing the same both synthetically and via expression of a corresponding sequence from a host transformed with a suitable vector carrying the corresponding DNA sequence. The various structural information provided by this invention enables the preparation of labeled or unlabeled immunospecific species, particularly antibodies, as well as nucleic acid probes labeled in conventional fashion. Pharmaceutical compositions and methods of using various products of this invention are also provided.Type: ApplicationFiled: August 21, 2001Publication date: September 5, 2002Applicant: Oregon Health Sciences University.Inventors: Olivier Civelli, James R. Bunzow, David K. Grandy, Curtis A. Machida
-
Patent number: 6437114Abstract: The present invention is directed toward the isolation, characterization and pharmacological use of the human D4 dopamine receptor. The nucleotide sequence of the gene corresponding to this receptor and alleleic variant thereof are provided by the invention. The invention also includes recombinant eukaryotic expression constructs capable of expressing the human D4 dopamine receptor in cultures of transformed eukaryotic cells. The invention provides cultures of transformed eukaryotic cells which synthesize the human D4 dopamine receptor, and methods for characterizing novel psychotropic compounds using such cultures.Type: GrantFiled: August 20, 1999Date of Patent: August 20, 2002Assignee: Oregon Health & Science UniversityInventors: Olivier Civelli, Hubert Henri-Marie Van Tol
-
Publication number: 20020082213Abstract: The present invention relates to a method of screening for a therapeutically useful compound which comprises testing an LC132 receptor agonist in a screening assay for psychiatric and/or neurological disorders. More particularly, the screening method is based on contacting an LC132 receptor with an agent suspected of being an agonist of the LC132 receptor function, followed by the detection of the binding and/or the agonist activity of the compound and then testing of an agent with LC132 agonist activity in an antiepileptic, anticonvulsant or anxiolytic screening assay.Type: ApplicationFiled: August 14, 2001Publication date: June 27, 2002Inventors: Olivier Civelli, James Richard Martin, Frederick Monsma, Jean-Luc Moreau, Hans-Peter Nothacker, Rainer Reinscheid
-
Patent number: 6406866Abstract: The present invention relates to a novel mammalian opioid receptor protein and ligands that bind to such proteins. The invention is directed toward the isolation, characterization and pharmacological use of an endogenous ligand that specifically binds to a novel mammalian opioid receptor protein heterologously expressed in mammalian cells. The invention specifically provides the isolated peptide ligand and analogues, derivatives and variants thereof. The invention specifically provides tyrosine substitution variants of the peptide ligand that specifically bind to the opioid receptor and can be radioiodinated. Also provided are methods of making such peptide ligands and methods of using the ligands for diagnostic and therapeutic uses and for the identification of other naturally-occurring or synthetic opioid receptor ligands.Type: GrantFiled: March 26, 1998Date of Patent: June 18, 2002Assignee: Oregon Health Sciences UniversityInventors: David K. Grandy, James R. Bunzow, Olivier Civelli, Rainer Klaus Reinscheid, Hans-Peter Nothacker, Frederick James Monsma
-
Publication number: 20020072072Abstract: The present invention provides an isolated nucleic acid molecule containing a nucleotide sequence which encodes an ADP-glucose receptor, and isolated polynucleotides therefrom. Also provided is an isolated ADP-glucose receptor polypeptide, an isolated immunogenic peptide therefrom, and antibodies specific therefor. The invention also provides a method of identifying an ADP-glucose receptor agonist or antagonist, by contacting an ADP-glucose receptor with one or more candidate compounds under conditions suitable for detection of a G-protein coupled signal in response to ADP-glucose, and identifying a candidate compound that alters production of the signal. Further provided is a method of identifying an ADP-glucose receptor ligand, by contacting an ADP-glucose receptor with one or more candidate compounds under conditions suitable for detecting selective binding of ADP-glucose to ADP-glucose receptor, and identifying a candidate compound that selectively binds the ADP-glucose receptor.Type: ApplicationFiled: February 9, 2001Publication date: June 13, 2002Inventors: Olivier Civelli, Hans-Peter Nothacker, Zhiwei Wang, Rainer Reinscheid
-
Patent number: 6383764Abstract: The invention provides a substantially pure Prolactin Releasing Peptide (PrRP) functional analog which suppresses absence seizures in a mammal, and related pharmaceutical compositions. The invention also provides a method of controlling absence seizures in a mammal, by administering to a mammal susceptible to absence seizures an effective amount of PrRP or a PrRP functional analog. Also provided are methods of identifying a compound that modulates AMPA receptor signaling in a mammal, by providing a compound that is a PrRP or PrRP functional analog, and determining the ability of the compound to modulate AMPA receptor signaling. The invention also provides methods of identifying a compound for controlling absence seizures in a mammal, by providing a compound that is a PrRP or PrRP functional analog, and determining the ability of the compound to control absence seizures in a mammal. Also provided are pharmaceutical compositions for controlling absence seizures in a mammal.Type: GrantFiled: April 28, 2000Date of Patent: May 7, 2002Assignee: The Regents of the University of CaliforniaInventors: Olivier Civelli, Steven Lin
-
Publication number: 20020037533Abstract: The invention provides methods of screening for a compound for promoting wakefulness in a mammal. The method is practiced by providing a compound that is a PrRP receptor agonist and determining the ability of the compound to promote wakefulness. Also provided by the invention are methods of screening for a compound for promoting sleep in a mammal. The methods are practiced by providing a compound that is a PrRP receptor antagonist and determining the ability of the compound to promote sleep. In addition, the invention provides a method of promoting wakefulness in a mammal. The method is practiced by administering to a mammal an effective amount of a PrRP receptor agonist. The invention further provides a method of promoting sleep in a mammal. The method is practiced by administering to a mammal an effective amount of a PrRP receptor antagonist.Type: ApplicationFiled: August 17, 2001Publication date: March 28, 2002Inventors: Olivier Civelli, Steven Lin
-
Patent number: 6342360Abstract: A mammalian D2 dopamine receptor gene has been cloned. Thus, DNA sequences encoding all or a part of the dopamine receptor are provided, as well as the corresponding polypeptide sequences and methods for producing the same both synthetically and via expression of a corresponding sequence from a host transformed with a suitable vector carrying the corresponding DNA sequence. The various structural information provided by this invention enables the preparation of labeled or unlabeled immunospecific species, particularly antibodies, as well as nucleic acid probes labeled in conventional fashion. Pharmaceutical compositions and methods of using various products of this invention are also provided.Type: GrantFiled: January 27, 1999Date of Patent: January 29, 2002Assignee: Oregon Health & Science UniversityInventors: Olivier Civelli, James R. Bunzow, David K. Grandy, Curtis A. Machida
-
Patent number: 6326156Abstract: The present invention relates to a method of screening for a therapeutically useful compound which comprises testing an LC132 receptor agonist in a screening assay for psychiatric and/or neurological disorders. More particularly, the screening method is based on contacting an LC132 receptor with an agent suspected of being an agonist of the LC132 receptor function, followed by the detection of the binding and/or the agonist activity of the compound and then testing of an agent with LC132 agonist activity in an antiepileptic, anticonvulsant or anxiolytic screening assay.Type: GrantFiled: June 3, 1997Date of Patent: December 4, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Olivier Civelli, James Richard Martin, Frederick Monsma, Jean-Luc Moreau, Hans-Peter Nothacker, Rainer Reinscheid
-
Patent number: 6280973Abstract: The present invention relates to a novel-mammalian methadone-specific opioid receptor protein and genes that encode such a protein. The invention is directed toward the isolation, characterization and pharmacological use of mammalian methadone-specific opioid receptor proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to the rat homologue of the mammalian methadone-specific opioid receptor gene. Also provided are recombinant expression constructs capable of expressing the mammalian methadone-specific opioid receptor genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian methadone-specific opioid receptor proteins encoded therein.Type: GrantFiled: February 22, 2000Date of Patent: August 28, 2001Assignee: Oregon Health & Science UniversityInventors: David K. Grandy, James R. Bunzow, Olivier Civelli